|
|
 Previous Article | Table of Contents | Next Article 
Thrombocytopoietic properties of oncostatin M
PM Wallace, JF MacMaster, JR Rillema, J Peng, SA Burstein and M Shoyab
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121,
USA.
Oncostatin M (OM) is a 28-kD glycoprotein that exhibits a panoply of
biologic effects. Based on histologic observations of increased splenic
megakaryocytes in nude mice implanted with an OM-secreting cell line, the
thrombocytopoietic properties of OM in mice were investigated in culture
and in vivo. Alone, OM did not induce megakaryocytic colony formation, but
in combination with murine interleukin-3 (IL-3), OM markedly enhanced
colony formation. The effects of OM on colony formation were similar to
those of IL-6. OM alone augmented acetylcholinesterase in short-term marrow
cultures. In normal mice, the administration of OM augmented platelet
counts without increasing other circulating blood cell counts. The
increment in counts exceeded that observed with IL-6. The kinetics of the
OM response suggested that maximal increases in platelets occurred 3 days
after the cessation of OM administration, irrespective of the duration of
administration. In irradiated mice, OM administration accelerated platelet
recovery and prevented the decrease in red blood cells observed in
irradiated control animals. The data show that OM behaves as a
megakaryocytic maturation factor in vitro and augments platelet production
in vivo. Based on these animal data, OM may have potential clinical utility
as a thrombocytopoietic agent.
Volume 86,
Issue 4,
pp. 1310-1315,
08/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T.S.-C. Juan, B. Bolon, R. A. Lindberg, Y. Sun, G. Van, and F. A. Fletcher
Mice Overexpressing Murine Oncostatin M (OSM) Exhibit Changes in Hematopoietic and Other Organs that Are Distinct from Those of Mice Overexpressing Human OSM or Bovine OSM
Vet. Pathol.,
January 1, 2009;
46(1):
124 - 137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Jenkins, A. W. Roberts, C. J. Greenhill, M. Najdovska, T. Lundgren-May, L. Robb, D. Grail, and M. Ernst
Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis
Blood,
March 15, 2007;
109(6):
2380 - 2388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tanaka, Y. Hirabayashi, T. Sekiguchi, T. Inoue, M. Katsuki, and A. Miyajima
Targeted disruption of oncostatin M receptor results in altered hematopoiesis
Blood,
November 1, 2003;
102(9):
3154 - 3162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Senaldi, B. C. Varnum, U. Sarmiento, C. Starnes, J. Lile, S. Scully, J. Guo, G. Elliott, J. McNinch, C. L. Shaklee, et al.
Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family
PNAS,
September 28, 1999;
96(20):
11458 - 11463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Loy, T. J. Davidson, K. K. Berry, J. F. Macmaster, B. Danle, and S. K. Durham
Oncostatin M: Development of a Pleiotropic Cytokine
Toxicol Pathol,
March 1, 1999;
27(2):
151 - 155.
[Abstract]
[PDF]
|
|
|
|
|
|
|
U. A.K. Betz, W. Bloch, M. van den Broek, K. Yoshida, T. Taga, T. Kishimoto, K. Addicks, K. Rajewsky, and W. Muller
Postnatally Induced Inactivation of gp130 in Mice Results in Neurological, Cardiac, Hematopoietic, Immunological, Hepatic, and Pulmonary Defects
J. Exp. Med.,
November 16, 1998;
188(10):
1955 - 1965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Agnello, C. Meazza, C. G. Rowan, P. Villa, P. Ghezzi, and G. Senaldi
Leptin causes body weight loss in the absence of in vivo activities typical of cytokines of the IL-6 family
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 1998;
275(3):
R913 - R919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
